BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
By M. Nikiforova, E. Kimura, M. Gandhi, P. Biddinger, J. Knauf, F. Basolo, Zhaowen Zhu, R. Giannini, G. Salvatore, A. Fusco and 3 more. Journal of Clinical Endocrinology and Metabolism, 2003
1,066 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/06cc16cdaf46fa657bb001faec28021b8ab5a3a1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Oncology
Citations in the corpus
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “The BRAF mutation is found in *80% of these tumors (156,466).”
- Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006, background): “BRAF mutations are found in 29–69% of papillary thyroid carcinoma but not in follicular thyroid carcinoma, and in up to 13% of poorly differentiated thyroid carcinoma and 35% of undifferentiated thyroid carcinom”
- BRAF mutation in thyroid cancer. (2005, background): “In some of the studies (Nikiforova et al. 2003, Xu et al. 2003, Fugazzola et al. 2004), a trend in association between BRAF mutation and lymph node metastasis was observed but did not achieve statistical significance.”
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (2012, background): “Other mutations, such as BRAF and RAS, are common in both well-differentiated thyroid cancer and ATCs and are likely to be early events in thyroid carcinogenesis that may predispose to tumor dedifferentiation (60,81).”